Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $6.95, for a total transaction of $34,750.00. Following the transaction, the chief technology officer directly owned 187,171 shares of the company’s stock, valued at approximately $1,300,838.45. This trade represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.10, for a total value of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Trading Down 7.9%

SOPHiA GENETICS stock traded down $0.54 during midday trading on Wednesday, reaching $6.30. 721,997 shares of the stock traded hands, compared to its average volume of 214,122. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The firm has a market cap of $528.51 million, a PE ratio of -12.12 and a beta of 0.96. The company has a 50-day simple moving average of $5.52 and a two-hundred day simple moving average of $5.11. SOPHiA GENETICS SA has a 12-month low of $2.96 and a 12-month high of $7.21.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. Research analysts expect that SOPHiA GENETICS SA will post -0.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SOPH has been the subject of a number of recent research reports. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright increased their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, BTIG Research upped their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Silverberg Bernstein Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the period. Dimensional Fund Advisors LP boosted its position in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares in the last quarter. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS during the 1st quarter worth $50,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth about $49,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: AstraZeneca collaboration: SOPHiA GENETICS entered a multiyear global agreement with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The deal could expand SOPH’s role in pharmaceutical clinical development and create longer-term commercial opportunities. SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
• Positive Sentiment: Higher full-year outlook: Management raised 2026 revenue guidance to $94 million-$96 million, representing 22%-24% year-over-year growth and exceeding the roughly $93.4 million consensus estimate. The company is also targeting adjusted EBITDA breakeven by year-end. SOPHiA GENETICS Outlines 2026 Revenue Outlook
• Positive Sentiment: Revenue and analyst support: Second-quarter revenue increased 27% year over year to $23.3 million, surpassing the $21.7 million consensus estimate. Adjusted EBITDA losses improved 27% year over year to $8.8 million. HC Wainwright raised its price target from $12 to $14 and BTIG lifted its target from $8 to $9; both firms maintained Buy ratings.
• Negative Sentiment: EPS miss and ongoing losses: SOPHiA GENETICS reported a quarterly loss of $0.26 per share, missing the $0.21 consensus loss estimate. Net loss remained $22.4 million, while reported gross margin declined to 64.6% from 67.0% a year earlier. These results may be driving caution despite the improved revenue outlook. SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.